XML 90 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Components - Additional Information (Detail) - USD ($)
 12 Months Ended 36 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2022
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]          
Other-than-temporary impairment loss       $ 0  
Net unbilled co-development revenue $ 0 $ 8,000,000   0  
Depreciation expense 10,017,000 10,170,000 $ 11,678,000    
API and bulk drug product price true-up 75,055,000 0   75,055,000  
Acquired in-process research and development asset 0 35,000,000   0  
Cash and cash equivalents 155,700,000 171,223,000   155,700,000  
Eluminex Agreements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Unbilled upfront payment   8,000,000.0     $ 8,000,000.0
Astellas Japan Agreement [Member]          
Schedule of Available-for-sale Securities [Line Items]          
API and bulk drug product price true-up 6,500,000     6,500,000  
Astellas Europe Agreement [Member]          
Schedule of Available-for-sale Securities [Line Items]          
API and bulk drug product price true-up 57,400,000     57,400,000  
AstraZeneca Agreements [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Net unbilled co-development revenue 17,500,000 9,100,000   17,500,000  
API and bulk drug product price true-up 11,200,000     11,200,000  
HiFiBiO Agreement [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Acquired in-process research and development asset   35,000,000.0      
Europe [Member] | Astellas Agreement [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Transfer price true up   49,800,000      
Foreign subsidiaries [Member]          
Schedule of Available-for-sale Securities [Line Items]          
Cash and cash equivalents $ 92,500,000 $ 91,200,000   $ 92,500,000